Your browser doesn't support javascript.
loading
Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
Song, Hao; Zhang, Jinna; Ning, Liang; Zhang, Honglai; Chen, Dong; Jiao, Xuelong; Zhang, Kejun.
Afiliação
  • Song H; Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Zhang J; Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Ning L; Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Zhang H; Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Chen D; Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Jiao X; Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
  • Zhang K; Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
Med Sci Monit ; 28: e936571, 2022 03 07.
Article em En | MEDLINE | ID: mdl-35250023
ABSTRACT
This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscript. Reference Vemurafenib Hao Song, Jinna Zhang, Liang Ning, Honglai Zhang, Dong Chen, Xuelong Jiao, Kejun Zhang. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit, 2018; 24 3002-3010. DOI 10.12659/MSM.910084.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Med Sci Monit Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Med Sci Monit Assunto da revista: MEDICINA Ano de publicação: 2022 Tipo de documento: Article